ACON and ACONW Related Headlines
Go Back- Aclarion says cash runway extends into 2028, ends equity facilities
- Aclarion Publishes 2026 Shareholder Letter from the Chairman
- Aclarion partners with Source Healthcare to expand Nociscan in Los Angeles
- Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation
- Aclarion raises $10.4 million, extends cash runway into 2028
- Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028
- Aclarion reports 114% quarterly growth in scan volumes, raises $22M
- Aclarion Provides 2025 Update and 2026 Corporate Outlook
- Aclarion enrolls first patients at Northwestern, Scripps sites for CLARITY trial
- Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data
- Aclarion publishes Nociscan article in spine surgery journal
- Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)
- Aclarion names Jason Brosniak commercial director for eastern U.S.
- Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.
- Aclarion hires Dan Isherwood as UK commercial director
- Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion
- Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH
- Aclarion reports 89% surge in scan volumes, advances trial
- Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst
- Aclarion presents MR spectroscopy pain biomarker tech at London conference
- Aclarion Announces Use of MR Spectroscopy for identifying Biomarkers of Discogenic Pain highlighted at Global Neuroscience Conference
- Aclarion to Present at the LD Micro Main Event XIX
- Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH
- Aclarion Presents at LSI Europe ’25 Highlighting Nociscan Technology and Key Value Drivers
- First Patients Enrolled at UHealth – University of Miami in Aclarion’s Pivotal CLARITY Trial
- Aclarion names Greg Gould as chief financial officer
- Aclarion Appoints Greg Gould as Chief Financial Officer
- Aclarion reports 132% growth in Nociscan scan volume
- Aclarion Provides Corporate Update Highlighting Scan Volume Growth and Key Upcoming Catalysts
- Aclarion (ACON) postpones annual shareholder meeting to July 21
- Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders
- First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial
- Aclarion to Present NOCISCAN Technology at Leading Spine Innovation Forum
- Aclarion Adds UHealth, University of Miami Miller School of Medicine as CLARITY Trial Site
ACON and ACONW Related Press Releases
Go Back- Aclarion Publishes 2026 Shareholder Letter from the Chairman
- Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation
- Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028
- Aclarion Provides 2025 Update and 2026 Corporate Outlook
- Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data
- Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)
- Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.
- Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion
- Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH
- Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst
- Aclarion Announces Use of MR Spectroscopy for identifying Biomarkers of Discogenic Pain highlighted at Global Neuroscience Conference
- Aclarion to Present at the LD Micro Main Event XIX
- Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH
- Aclarion Presents at LSI Europe ’25 Highlighting Nociscan Technology and Key Value Drivers
- First Patients Enrolled at UHealth – University of Miami in Aclarion’s Pivotal CLARITY Trial
- Aclarion Appoints Greg Gould as Chief Financial Officer
- Aclarion Provides Corporate Update Highlighting Scan Volume Growth and Key Upcoming Catalysts
- Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders
- First Patient Enrolled in Aclarion’s Groundbreaking CLARITY Trial
- Aclarion to Present NOCISCAN Technology at Leading Spine Innovation Forum
- Aclarion Adds UHealth, University of Miami Miller School of Medicine as CLARITY Trial Site
